Final Study Completed for Cingulate’s Lead Asset CTx-1301
07 janv. 2025 07h30 HE
|
Cingulate Inc.
No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...
Oral Proteins and Peptides Market Report 2025: Key Trends Shaping the Market Over the Next Ten Years and Beyond
02 janv. 2025 04h22 HE
|
Research and Markets
Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The "Oral Proteins and Peptides Market Report" has been added to ResearchAndMarkets.com's offering.The oral proteins and peptides market size has grown...
1,202 Drug Delivery Collaboration and Licensing Deals Trends Report and Directory 2024 by Company A-Z, Deal Type and Therapeutic Target
31 déc. 2024 05h31 HE
|
Research and Markets
Dublin, Dec. 31, 2024 (GLOBE NEWSWIRE) -- The "Drug Delivery Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Drug Delivery Collaboration and...
India Drug Delivery Devices Market 2024, with Profiles of Pfizer, Novartis, GlaxoSmithKline, India Medtronic, Cardinal Health, B. Braun Medical, Sun Pharmaceutical, 3M, Cipla & Bayer Zydus Pharma
10 déc. 2024 07h25 HE
|
Research and Markets
Dublin, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The "India Drug Delivery Devices Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...
Oral Proteins & Peptides Market Research: Semaglutide, Linaclotide, Calcitonin,GLP-1 Receptor Agonist, GEP, CGRP, Diabetes, Gastroenterology, Genetic Disorder - Global Forecast to 2029
08 nov. 2024 11h32 HE
|
Research and Markets
Dublin, Nov. 08, 2024 (GLOBE NEWSWIRE) -- The "Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic...
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
07 nov. 2024 07h30 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
08 oct. 2024 15h15 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed...
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
15 août 2024 07h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
09 août 2024 16h15 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
$375+ Billion Drug Delivery Devices Markets - Global Industry Size, Share, Trends, Opportunity, and Forecasts, 2019-2023 and 2024-2029F
08 mai 2024 09h01 HE
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ...